Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871943 | 1.00 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL3625234 | 1.00 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL3625229 | 0.86 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL1694877 | 0.86 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL3786370 | 0.86 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL8088686 | 0.86 | HCAR2 (0.61) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL6267290 | 0.84 | HCAR2 (0.59) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL6392245 | 0.84 | HCAR2 (0.59) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL25961164 | 0.84 | HCAR2 (0.59) | HCAR2KMT2AALDH1A1TP53HSD17B10 | |
| SCHEMBL871942 | 0.84 | HCAR2 (0.59) | HCAR2KMT2AALDH1A1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324202-B2 | 5-phenyl-1H-benzo [E] [1,4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2012-12-04 | — | — | US | claimed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-2231623-B1 | 5-PHENYL-1H-BENZO[E][1, 4]DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS | UNIV FIRENZE (IT) | 2013-05-22 | — | — | EP | disclosed |
| US-8324202-B2 | 5-phenyl-1H-benzo [E] [1,4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2012-12-04 | — | — | US | disclosed |
| US-20100331316-A1 | 5-PHENYL-LH-BENZ0 [E] [1,4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS | A.I.L. FIRENZE SEZIONE AUTONOMA DI FIRENZE DELL'ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMA - ONLUS (IT) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-20100331316-A1 | 5-PHENYL-LH-BENZ0 [E] [1,4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS | HDAC10, HDAC1, HDAC5 | HCAR2 931/4885KMT2A 71/4885ALDH1A1 415/4885 |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | TYMP, PNP, SAMHD1 | HCAR2 3853/4885KMT2A 4081/4885ALDH1A1 770/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | HCAR2 4109/4885KMT2A 3756/4885ALDH1A1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.